GET DAILY SIGNALSPDS Biotechnology (PDSB) Analysts See +337% Upside to $4.50 Target
Key Takeaways
- The central target of $4.50 represents the arithmetic mean of three verified analyst price targets, spanning a range of $4.00 to $5.00.
- From a recent close of $1.03, reaching $4.50 would imply a roughly 337% advance — a substantial move by any measure.
- PDS Biotechnology Corporation (PDSB) is a clinical-stage immunotherapy developer focused on its lead program, PDS0301.
- Pipeline refocus and Buy ratings provide the main support, while funding needs and clinical-execution risks remain key hurdles.
- The tight target range reflects broad optimism around the platform rather than precise agreement on valuation.
- Readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages for deeper coverage.
- For broader market ideas, explore Trending AI Robots.
Analyst Consensus and Price Targets
PDS Biotechnology Corporation (PDSB) develops targeted cancer immunotherapies using its Versamune platform. I reviewed three specific analyst targets for this piece: H.C. Wainwright at $5.00 (reiterated October 15, 2026), B. Riley Securities at $4.00 (raised from $3.00 on October 29, 2026), and Alliance Global Partners at $4.50. Their average comes to $4.50, which I use as the central target, with a range from $4.00 to $5.00.
All three firms maintain Buy-equivalent ratings, leading aggregators to describe the consensus as “Strong Buy” or “Moderate Buy.” The targets sit close together in absolute terms even as they suggest substantial percentage gains from current levels. H.C. Wainwright has lowered its target over time from $15 to $7 to $5 as the company sharpened its focus, while B. Riley raised its figure after recent program updates. Differences among the calls mainly stem from varying views on dilution, funding needs, and clinical success probabilities rather than doubts about the underlying technology.
Current Share Price and Path to the Target
Shares recently closed near $1.03, inside a 52-week range of about $0.20 to $1.79. Closing the gap to the $4.50 central target from here would mean an advance of roughly 337%, a sizable move. The stock has shown volatility, easing from around $1.50 in early November as selling pressure built, which is typical for small-cap clinical biotechs sensitive to sentiment and liquidity.
With no product revenue yet, progress depends on clinical milestones rather than earnings. The company has narrowed its efforts to PDS0301, an immunotherapy pairing Versamune with an IL-12 antibody-drug conjugate. This followed a roughly 36% workforce reduction in August 2026 and a shift to pursue the PDS0101 HPV program through partnerships. A positive Phase 3 result or a meaningful partnership could serve as a catalyst, though a $50 million at-the-market facility introduces dilution pressure.
Factors That Could Support a Move Higher
- Pipeline focus on PDS0301: Directing resources toward one potentially broad immuno-oncology program may improve execution and investor clarity.
- Analyst support: Buy ratings from all three firms and the recent B. Riley target increase show ongoing conviction.
- Catalyst potential: Strong Phase 3 data or a partnership could lift valuation for a company with roughly $100 million in market capitalization.
- Low share price: Modest absolute price changes can produce large percentage moves, though the reverse also applies.
Risks That Could Keep the Target Out of Reach
- Funding and dilution: As a pre-revenue clinical company, capital raises are likely and can dilute existing shareholders.
- Clinical risk: An unsuccessful or unclear trial outcome for PDS0301 would damage the investment case.
- Concentration risk: Relying on a single lead program heightens binary outcomes.
- Valuation pressure: Small-cap biotechs often face steep discounts when risk appetite declines.
Technical Picture and Market Structure
The 52-week low near $0.20 and high near $1.79 create a wide trading band. The $1.00 level currently serves as a psychological support area under test, while the $1.50–$1.53 zone from early November offers nearby overhead resistance. Any sustained advance beyond that zone would require confirmation through volume to signal a real shift in trend.
Time Horizon and Key Items to Watch
Analyst targets typically look out about 12 months, though exact horizons vary. Near-term focus falls on the next earnings report around November 24, 2026, along with updates on cash runway, the PDS0301 development schedule, and any partnership or financing news. Revisions to analyst targets, which have occurred often for this name, and broader biotech sentiment plus interest-rate expectations also merit attention. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Using AI Signals in Volatile Names
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical patterns, and data-driven analysis. For a catalyst-driven name like PDSB, these signals can assist in spotting momentum shifts and monitoring positions alongside traditional research.
Overall View
The $4.50 central target, drawn from three verified analyst calls between $4.00 and $5.00, points to a roughly 337% advance from the recent price near $1.03. It reflects analyst optimism about the refocused PDS0301 program and platform potential rather than a guaranteed outcome. Achieving it would likely need successful clinical progress, positive data, and careful capital management. Offsetting that are real funding, dilution, and binary clinical risks that could push the stock lower. Monitoring the upcoming earnings, PDS0301 timeline, and target revisions remains important while balancing both the upside case and the uncertainties typical of early-stage biotech.
Tickeron AI Tools in My Research
I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The platform helps surface momentum changes in volatile stocks through continuous AI monitoring, which complements my review of analyst targets and clinical updates. It is one of several tools I use to stay organized when tracking clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
PDSB's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 73 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement